MUNICH — Neoadjuvant treatment with nivolumab and ipilimumab induced major pathologic response in 100% of patients with early-stage, mismatch repair-deficient colon cancers, according to results of the phase 2 NICHE trial presented at European Society for Medical Oncology Congress.
Immune checkpoint inhibition has become a standard treatment approach for many cancer types.
These agents are of particular interest in mismatch repair-deficient tumors because they have high mutational load and upregulation of immune checkpoints, according to Myriam Chalabi, MD, PhD, oncologist in the

Source link